HeartBeam Inc. Pioneers Cable-Free ECG System for At-Home Cardiac Monitoring
TL;DR
HeartBeam's FDA-cleared, cable-free ECG system offers a competitive edge in the $500 million concierge market with its patented, high-margin technology for immediate cardiac symptom recording.
HeartBeam's system synthesizes a 12-lead ECG from 3D signals in 30 seconds, utilizing proprietary hardware and software for arrhythmia assessment, now under FDA review.
HeartBeam's innovative ECG technology enhances cardiac care accessibility, enabling early detection and timely treatment for patients anywhere, improving global heart health outcomes.
Discover HeartBeam's breakthrough in cardiac care: a cable-free ECG system that records your heart's activity in 30 seconds, anywhere, anytime, with 20 patents backing its innovation.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam Inc. (NASDAQ: BEAT) has made significant strides in cardiac care technology with its development of the first cable-free system capable of synthesizing a 12-lead ECG from 3D, non-coplanar electrical signals in real time. This innovation allows patients to carry the HeartBeam System with them at all times, ready to record an ECG in just 30 seconds whenever symptoms arise, whether at home or elsewhere. The system's ability to reduce delays in care by enabling immediate symptom recording is a game-changer for patients and healthcare providers alike.
The HeartBeam System has already received FDA clearance for arrhythmia assessment, with its 12-lead ECG synthesis software currently under FDA review for the same indication. A recent partnership with AccurKardia further enhances HeartBeam's arrhythmia solution by incorporating an FDA-cleared automated rhythm interpretation software. With 20 issued patents and more pending, HeartBeam's proprietary technology is well-protected, covering its hardware, software, and algorithmic capabilities.
Targeting a $500 million concierge SAM and a broader multibillion-dollar patient pay market, HeartBeam is on the verge of commercial launch. Its high-margin, recurring revenue model supports the company's vision to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside traditional medical settings. This breakthrough not only promises to improve patient outcomes by facilitating timely care but also significantly reduces the need for wires, complex setups, or clinical staff, making synthesized 12-lead ECG signals accessible beyond the confines of a medical facility.
Curated from InvestorBrandNetwork (IBN)
